Life Sciences IP Review

17/07/2025

Experts from Goodwin Law, Invivyd, and New England Biolabs unpack the ongoing challenges of patent eligibility under 35 U.S.C. § 101, focusing on genetic innovations and diagnostics.

Moderator Michael Shuster leads a dynamic discussion with Erica LoRe and Guy Birkenmeier on how shifting case law and USPTO guidance are shaping life sciences IP strategy.

Watch the full panel to explore how top counsel are navigating § 101 hurdles: https://ow.ly/eTN550Wrh7q

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

17/07/2025

Brownstein has recruited five partners from Crowell & Moring, including Anne Elise Herold Li and Paul Keller, who join the IP team in New York.

Also joining are Aaron Cummings, Jim Flood, and Evan Chuck—bringing policy and life sciences depth to the Government Relations Department.

Rich Benenson calls it a “pivotal moment” for the firm’s growth.

Read more about the hires and what they bring to the table: https://ow.ly/7n7T50WrgWc

US firm Brownstein nabs five from Crowell ‘at pivotal moment’

17/07/2025

American Regent has scored a rare preliminary injunction in a Hatch-Waxman case, successfully blocking Eugia’s attempt to launch a generic version of its Selenious Acid Injection.

The ruling follows allegations of patent infringement tied to Eugia’s ANDA filings.

Explore how this unexpected win could reshape the generics landscape: https://ow.ly/1iv750WrgGq

American Regent secures rare PI win in Hatch-Waxman dispute

17/07/2025

AstraZeneca has lost its appeal in the Court of Appeal of England and Wales, which upheld an earlier ruling that its patent for Type 2 diabetes drug Forxiga is invalid.

The decision favours Teva, Viatris, and Glenmark, despite AstraZeneca’s attempts to extend protection through SPCs until 2028.

Uncover the full story behind this high-stakes patent battle: https://ow.ly/h6u850WrgwO

AstraZeneca suffers defeat over $7bn diabetes patent

16/07/2025

Powell Gilbert is expanding into Düsseldorf this September, hiring top German patent litigator Andreas Kramer and his team from Vossius to strengthen its UPC and pan-European litigation offering.

This strategic move marks a major step in the firm’s European growth.

Read how it positions them in the UPC landscape: https://ow.ly/Nw9L50Wqnbc

Powell Gilbert launches Düsseldorf office with leading patent litigator

16/07/2025

Much Shelist has added Patrick Richards as a partner in its IP group in Chicago, bringing deep experience in IP litigation, licensing, and monetisation.

A former K&L Gates attorney and serial entrepreneur, Richards has also co-founded two software businesses and is active in the litigation funding space.

Learn how Richards’ unique mix of legal and entrepreneurial expertise is set to bolster the firm’s IP offering: https://ow.ly/JM2e50Wqn99

16/07/2025

Africa’s battle against hunger depends on agricultural innovation—and the Arusha Protocol offers critical protection for plant breeders driving this change, says ARIPO.

With 600 million people projected to face severe hunger by 2030, boosting food security is both urgent and essential.

Discover why PVP could be the key to Africa’s sustainable agricultural future: https://ow.ly/bLUS50Wqn7W

Explainer: ARIPO’s role in Plant Variety Protection

16/07/2025

Johnson & Johnson has filed lawsuits against Sun Pharma to block its proposed generic version of schizophrenia drug Invega Sustenna, citing infringement of a key dosing patent.

The move follows a recent legal win for J&J against two other generics over the same treatment.

Explore what this means for generic challengers and J&J’s IP defence strategy: https://ow.ly/uU4l50Wqn4p

J&J sues over schizophrenia drug generic following patent victory

16/07/2025

After nearly three decades at Bayer, IP veteran Jörg Thomaier will retire this autumn, handing over leadership to Dorian Immler.

Thomaier, who led major IP integrations and litigation efforts, will remain as senior IP advisor during the transition.

Discover their views on strategy, SPCs, and the future of IP at Bayer: https://ow.ly/gwo550Wqn31

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

11/07/2025

Last chance alert!

Save $700 on your ticket to LSPN North America–Fall — but only until midnight tonight!

Join global IP leaders in San Francisco (Oct 21–22) as they unpack cutting-edge strategies for protecting and leveraging innovation in life sciences.

Confirmed attendees include experts from:
🔹 Amgen
🔹 Johnson & Johnson
🔹 Gilead Sciences
🔹 Novartis
🔹 Thermo Fisher
🔹 10x Genomics
…and many more.

Secure your spot, grow your network, and leave with insights you can act on immediately.

🎟 Book now to lock in your $700 savings → https://ow.ly/QwCH50WmTSr

11/07/2025

Hazel Ford and Alex Robinson of Mathys & Squire unpack how recent shifts at the EPO Boards of Appeal and the rise of Unified Patent Court rulings are shaping pan-European patent strategy.

The session explores what these developments mean for patent applicants navigating the evolving European IP landscape.

Watch the full discussion for key insights into EPO and UPC dynamics: https://ow.ly/4Tou50Wo95p

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

11/07/2025

Kilpatrick has added trademark and copyright veteran Peter Willsey as a partner in its Washington, DC office.

Willsey, formerly global chair of the same practice at Brown Rudnick, brings 30+ years of IP expertise to the firm.

Discover why Kilpatrick’s Alicia Grahn Jones says clients will benefit from his arrival: https://ow.ly/qlgk50Wo94W

Kilpatrick adds ‘seasoned litigator’ as trademark partner